GTBP (GT Biopharma Corporation) מכפיל P/E עתידי

The forward P/E ratio of GT Biopharma, Inc. (GTBP) currently stands at 0.00 according to historical dynamics on the GURU.Markets chart. A lack of sales due to early-stage testing deprives GT Biopharma, Inc. (GTBP) of pricing power. Drug development is based on AI and TriKE automation, while business success relies on patent protection and the efficacy of new immune cell activation methods.

GT Biopharma, Inc. (GTBP) develops immuno-oncology solutions whose value depends on clinical trial results rather than macroeconomic conditions. The ratio of the current share price to projected earnings for the following year allows for an assessment of market expectations; therefore, the company's expected P/E multiple helps investors filter out noise and determine the fair value of the business during periods of high volatility.